International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announced on Wednesday that it has secured a significant enterprise imaging contract with UZ Leuven, Belgium's largest university hospital. This agreement allows UZ Leuven to implement Sectra's digital pathology module, streamlining primary diagnostics for pathologists and improving efficiency for both clinicians and patients in cancer care.
Recognised as the best hospital in Belgium by Newsweek and ranked among the top 50 globally, UZ Leuven stands out as a major healthcare provider in the region. The 10-year contract, part of Sectra's fiscal year 2024/2025, reflects a commitment to advancing diagnostic capabilities.
Sectra's digital pathology solution is integrated within its broader enterprise imaging framework, promoting a unified approach to imaging while optimising operational costs. The scalable system, centred around a Vendor Neutral Archive (VNA), facilitates growth across various medical specialities and institutions.
Founded in 1978 and headquartered in Linköping, Sweden, Sectra is dedicated to enhancing healthcare efficiency globally. In the 2023/2024 fiscal year, the company reported sales of SEK2,964m.
Imugene announces Azer-cel Phase 1b clinical trial data
CARsgen successfully defends European GPC3 CAR-T patent
IGI and AbbVie enter global licensing agreement for ISB 2001
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
SciBase introduces Nevisense pilot at Florida research university
Exact Sciences secures Medicare coverage for Oncodetect MRD test in colorectal cancer
Tyra Biosciences to announce TYRA-300 preclinical results at ENDO 2025
Centivax raises USD45m to commercialise universal flu vaccine
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Avenzo Therapeutics doses first patient in AVZO-1418/DB-1418 Phase 1/2 clinical study